News & Updates
Filter by Specialty:

Survival in mCRPC prolonged with talazoparib–enzalutamide combo
08 Mar 2025
byJairia Dela Cruz
The combination of the PARP inhibitor talazoparib plus the androgen receptor-pathway inhibitor enzalutamide yields a clinically meaningful increase in the overall survival of patients with metastatic castration-resistant prostate cancer (mCRPC) being treated in the first-line setting when compared with enzalutamide alone, according to final data from the phase III TALAPRO-2 trial.
Survival in mCRPC prolonged with talazoparib–enzalutamide combo
08 Mar 2025
Does using GLP-1 RAs induce suicide in T2D patients?
08 Mar 2025
byStephen Padilla
Patients with type 2 diabetes (T2D) who use glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) appear to have no increased risk of suicidality when compared with the use of dipeptidyl peptidase-4 inhibitors (DPP-4is) or sodium-glucose cotransporter-2 inhibitors (SGLT-2is), a study has found.